Literature DB >> 19066981

[High-dose buprenorphine for outpatient palliative pain therapy].

K Gastmeier1, E Freye.   

Abstract

The case of a 78-year-old patient with cancer-related pain and additionally mixed-pain syndrome is presented. Pain therapy with buprenorphine TTS 210 microg/h every 3 days was sufficient in the beginning, later the therapy was changed because of increasing problems of tape fixing during fever periods under chemotherapy to a continuous infusion of buprenorphine intravenously via an external medication pump. During the course of therapy it became necessary to increase the dose to 99.9 mg/day buprenorphine. Under this medication a sufficient pain reduction (median NRS 2-3) over a period of 135 days could be achieved. At the same time the patient was vigilant and cooperative without signs of intoxication until the end of life at home in the presence of his family.If no signs of intoxication occur under extreme opioid therapy and a sufficient pain therapy can be achieved, a rotation to another opioid is not necessary. However, outpatient palliative care requires a frequent adaptation to the individually varying opioid demand of the patient and time-consuming nursing care.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19066981     DOI: 10.1007/s00482-008-0742-9

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  43 in total

1.  Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model.

Authors:  Wolfgang Koppert; Harald Ihmsen; Nicole Körber; Andreas Wehrfritz; Reinhard Sittl; Martin Schmelz; Jürgen Schüttler
Journal:  Pain       Date:  2005-09-09       Impact factor: 6.961

2.  Opioid-induced hyperalgesia and rapid opioid detoxification after tacrolimus administration.

Authors:  Antonio Siniscalchi; Emanuele Piraccini; Zuzana Miklosova; Stefania Taddei; Stefano Faenza; Gerardo Martinelli
Journal:  Anesth Analg       Date:  2008-02       Impact factor: 5.108

Review 3.  Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure.

Authors:  Michael H Ossipov; Josephine Lai; Tamara King; Todd W Vanderah; Frank Porreca
Journal:  Biopolymers       Date:  2005       Impact factor: 2.505

4.  Buprenorphine in a transdermal therapeutic system--a new option.

Authors:  K Böhme
Journal:  Clin Rheumatol       Date:  2002-02       Impact factor: 2.980

5.  Mutagenesis of the mouse delta opioid receptor converts (-)-buprenorphine from a partial agonist to an antagonist.

Authors:  G Bot; A D Blake; S Li; T Reisine
Journal:  J Pharmacol Exp Ther       Date:  1998-01       Impact factor: 4.030

Review 6.  Relationships among morphine metabolism, pain and side effects during long-term treatment: an update.

Authors:  Gertrud Andersen; Lona Christrup; Per Sjøgren
Journal:  J Pain Symptom Manage       Date:  2003-01       Impact factor: 3.612

7.  In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions.

Authors:  J E Dum; A Herz
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

8.  [Time used for outpatient tumor pain therapy].

Authors:  K Gastmeier
Journal:  Schmerz       Date:  1999-08-19       Impact factor: 1.107

9.  Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers.

Authors:  Luis R Gardell; Ruizhong Wang; Shannon E Burgess; Michael H Ossipov; Todd W Vanderah; T Philip Malan; Josephine Lai; Frank Porreca
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

10.  Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.

Authors:  Mark K Greenwald; Chris-Ellyn Johanson; David E Moody; James H Woods; Michael R Kilbourn; Robert A Koeppe; Charles R Schuster; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

View more
  2 in total

1.  The nociceptin/orphanin FQ receptor system as a target to alleviate cancer-induced bone pain in rats: Model validation and pharmacological evaluation.

Authors:  Sonny H J Sliepen; Johanna Korioth; Thomas Christoph; Thomas M Tzschentke; Marta Diaz-delCastillo; Anne-Marie Heegaard; Kris Rutten
Journal:  Br J Pharmacol       Date:  2020-01-21       Impact factor: 8.739

2.  Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain.

Authors:  Wojciech Leppert; Grzegorz Kowalski
Journal:  Onco Targets Ther       Date:  2015-12-04       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.